Maryalice Stetler-Stevenson

Maryalice Stetler-Stevenson

UNVERIFIED PROFILE

Are you Maryalice Stetler-Stevenson?   Register this Author

Register author
Maryalice Stetler-Stevenson

Maryalice Stetler-Stevenson

Publications by authors named "Maryalice Stetler-Stevenson"

Are you Maryalice Stetler-Stevenson?   Register this Author

100Publications

-Reads

Flow Cytometric Monitoring for Residual Disease in B Lymphoblastic Leukemia Post T Cell Engaging Targeted Therapies.

Curr Protoc Cytom 2018 Sep 13:e44. Epub 2018 Sep 13.

Laboratory of Pathology, CCR, NIH, Bethesda, Maryland.

View Article
September 2018

T Cells Genetically Modified to Express an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma.

J Clin Oncol 2018 Aug 29;36(22):2267-2280. Epub 2018 May 29.

Jennifer N. Brudno, Irina Maric, Steven D. Hartman, Jeremy J. Rose, Norris Lam, Maryalice Stetler-Stevenson, Dalia Salem, Constance Yuan, Steven Pavletic, Jennifer A. Kanakry, Lekha Mikkilineni, Steven A. Feldman, David F. Stroncek, Brenna G. Hansen, Rashmika Patel, Frances Hakim, Ronald E. Gress, and James N. Kochenderfer, National Institutes of Health, Bethesda; Syed Abbas Ali, Johns Hopkins University Sidney Kimmel Comprehensive Cancer Center, Baltimore; Judith Lawrence, Leidos Biomedical Research, Frederick, MD; Michael Wang, University of Texas MD Anderson Cancer Center, Houston, TX; and Dalia Salem, Mansoura University, Mansoura, Egypt.

View Article
August 2018

Tumor-Derived GM-CSF Promotes Granulocyte Immunosuppression in Mesothelioma Patients.

Clin Cancer Res 2018 Jun 30;24(12):2859-2872. Epub 2018 Mar 30.

Thoracic and GI Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.

View Article
June 2018

Early recovery of circulating immature B cells in B-lymphoblastic leukemia patients after CD19 targeted CAR T cell therapy: A pitfall for minimal residual disease detection.

Cytometry B Clin Cytom 2018 May 31;94(3):434-443. Epub 2017 Oct 31.

Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.

View Article
May 2018

5-Azacytidine prevents relapse and produces long-term complete remissions in leukemia xenografts treated with Moxetumomab pasudotox.

Proc Natl Acad Sci U S A 2018 02 5;115(8):E1867-E1875. Epub 2018 Feb 5.

Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892;

View Article
February 2018

Report of the results of the International Clinical Cytometry Society and American Society for Clinical Pathology workload survey of clinical flow cytometry laboratories.

Cytometry B Clin Cytom 2017 11 3;92(6):525-533. Epub 2016 Aug 3.

Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.

View Article
November 2017

Myeloma minimal residual disease testing in the United States: Evidence of improved standardization.

Am J Hematol 2016 12 11;91(12):E502-E503. Epub 2016 Oct 11.

Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.

View Article
December 2016

Consensus guidelines for myeloma minimal residual disease sample staining and data acquisition.

Cytometry B Clin Cytom 2016 Jan 6;90(1):26-30. Epub 2015 Jul 6.

HMDS, Department of Haematology, St, James's Institute of Oncology, Leeds, Ls9, 7TF, United Kingdom.

View Article
January 2016

Assessment of minimal residual disease in myeloma and the need for a consensus approach.

Cytometry B Clin Cytom 2016 Jan 23;90(1):21-5. Epub 2015 Sep 23.

Laboratory of Pathology, NCI, Bethesda, Maryland, 20892.

View Article
January 2016

Characterization of CD22 expression in acute lymphoblastic leukemia.

Pediatr Blood Cancer 2015 Jun 1;62(6):964-9. Epub 2015 Mar 1.

Pediatric Oncology Branch, Center for Cancer Research (CCR), National Cancer Institute (NCI), NIH, Bethesda, Maryland.

View Article
June 2015

Minimal residual disease in multiple myeloma: bringing the bench to the bedside.

Nat Rev Clin Oncol 2015 May 27;12(5):286-95. Epub 2015 Jan 27.

Myeloma Service, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA.

View Article
May 2015

Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor.

J Clin Oncol 2015 Feb 25;33(6):540-9. Epub 2014 Aug 25.

James N. Kochenderfer, Mark E. Dudley, Sadik H. Kassim, Robert P.T. Somerville, Robert O. Carpenter, Maryalice Stetler-Stevenson, James C. Yang, Q. Phan, Marybeth S. Hughes, Richard M. Sherry, Mark Raffeld, Steven Feldman, Lily Lu, Yong F. Li, Lien T. Ngo, Debbie-Ann N. Nathan, Kathleen E. Morton, Mary Ann Toomey, and Steven A. Rosenberg, National Cancer Institute; Clara C. Chen, Clinical Center, National Institutes of Health (NIH); Sarah M. Kranick and Avindra Nath, National Institutes of Neurologic Disorders and Stroke, NIH, Bethesda, MD; Andre Goy and Tatyana Feldman, Hackensack University Medical Center, Hackensack, NJ; David E. Spaner, Sunybrook Odette Cancer Center, Toronto, Ontario, Canada; and Michael L. Wang, MD Anderson Cancer Center, Houston, TX.

View Article
February 2015

Paradoxical central nervous system immune reconstitution syndrome in acquired immunodeficiency syndrome-related primary central nervous system lymphoma.

Haematologica 2015 Jan 10;100(1):e21-4. Epub 2014 Oct 10.

HIV & AIDS Malignancy Branch, Center for Cancer Research, National Cancer Institute; National Institutes of Health

View Article
January 2015

A phase II trial of pan-KIR2D blockade with IPH2101 in smoldering multiple myeloma.

Haematologica 2014 Jun 21;99(6):e81-3. Epub 2014 Mar 21.

Multiple Myeloma Section, Metabolism Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA Myeloma Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USA

View Article
June 2014

Minimal residual disease: what are the minimum requirements?

J Clin Oncol 2014 Feb 13;32(5):475-6. Epub 2014 Jan 13.

Center for Cancer Research, National Institutes of Health, Bethesda, MD.

View Article
February 2014

Monoclonal B-cell lymphocytosis in donors.

Blood 2014 Feb;123(9):1281-2

NATIONAL CANCER INSTITUTE.

View Article
February 2014

Quantification of expression of antigens targeted by antibody-based therapy in chronic lymphocytic leukemia.

Am J Clin Pathol 2013 Dec;140(6):813-8

Flow Cytometry Unit, Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 10 Center Dr, Bethesda, MD, 20892;

View Article
December 2013

Cladribine with immediate rituximab for the treatment of patients with variant hairy cell leukemia.

Clin Cancer Res 2013 Dec 25;19(24):6873-81. Epub 2013 Nov 25.

Authors' Affiliations: Laboratories of Molecular Biology, Pathology, and Metabolism Branch, National Cancer Institute; and Department of Laboratory Medicine, Clinical Center, NIH, Bethesda, Maryland.

View Article
December 2013

Bendamustine and rituximab in relapsed and refractory hairy cell leukemia.

Clin Cancer Res 2013 Nov 4;19(22):6313-21. Epub 2013 Oct 4.

Authors' Affiliations: Laboratories of Molecular Biology and Pathology, and Metabolism Branch, National Cancer Institute, NIH, Bethesda, Maryland.

View Article
November 2013

Rapid complete donor lymphoid chimerism and graft-versus-leukemia effect are important in early control of chronic lymphocytic leukemia.

Exp Hematol 2013 Sep 18;41(9):772-8. Epub 2013 May 18.

Experimental Transplantation and Immunology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.

View Article
September 2013

Distinguishing hairy cell leukemia variant from hairy cell leukemia: development and validation of diagnostic criteria.

Leuk Res 2013 Apr 22;37(4):401-409. Epub 2013 Jan 22.

Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. Electronic address:

View Article
April 2013

Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia.

Blood 2013 Feb 14;121(7):1165-74. Epub 2012 Dec 14.

Pediatric Oncology Branch, Center for Cancer Research (CCR), National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, MD 20892, USA.

View Article
February 2013

Myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation: diagnostic and therapeutic challenges.

Am J Hematol 2012 Sep 4;87(9):916-22. Epub 2012 Apr 4.

Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.

View Article
September 2012

Flow cytometry increases the sensitivity of detection of leukemia and lymphoma cells in bronchoalveolar lavage specimens.

Cytometry B Clin Cytom 2012 Sep 26;82(5):305-12. Epub 2012 Jul 26.

Hematopathology Section, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.

View Article
September 2012

Case study interpretation--Portland: Case 1. Hairy cell leukemia with CLL-like monoclonal B lymphocytosis.

Cytometry B Clin Cytom 2012 May 19;82(3):177-9. Epub 2012 Mar 19.

Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA.

View Article
May 2012

Both variant and IGHV4-34-expressing hairy cell leukemia lack the BRAF V600E mutation.

Blood 2012 Apr 30;119(14):3330-2. Epub 2011 Dec 30.

Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.

View Article
April 2012

Flow cytometric immunophenotypic assessment of T-cell clonality by vβ repertoire analysis in fine-needle aspirates and cerebrospinal fluid.

Am J Clin Pathol 2012 Feb;137(2):220-6

Flow Cytometry Unit, Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.

View Article
February 2012

Phase I trial of 7-hydroxystaurosporine and fludararbine phosphate: in vivo evidence of 7-hydroxystaurosporine induced apoptosis in chronic lymphocytic leukemia.

Leuk Lymphoma 2011 Dec 12;52(12):2284-92. Epub 2011 Jul 12.

Laboratory of Stem Cell Biology, Cellular and Tissue Therapy Branch, Division of Cell and Gene Therapies,Office of Cellular, Tissues and Gene Therapies, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.

View Article
December 2011

Diagnosis of hairy cell leukemia by flow cytometry.

Leuk Lymphoma 2011 Jun 19;52 Suppl 2:11-3. Epub 2011 Apr 19.

Flow Cytometry Unit, Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.

View Article
June 2011

Recombinant immunotoxins and other therapies for relapsed/refractory hairy cell leukemia.

Leuk Lymphoma 2011 Jun;52 Suppl 2:82-6

Laboratory of Molecular Biology, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.

View Article
June 2011

Flow cytometry immunophenotyping of hematolymphoid neoplasia.

Methods Mol Biol 2011 ;699:295-316

Department of Laboratory Medicine, Hematology Section, National Institutes of Health Clinical Center, Bethesda, MD, USA.

View Article
May 2011

Evidence of canonical somatic hypermutation in hairy cell leukemia.

Blood 2011 May 2;117(18):4844-51. Epub 2011 Mar 2.

Laboratories of Molecular Biology, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.

View Article
May 2011

Variables affecting the quantitation of CD22 in neoplastic B cells.

Cytometry B Clin Cytom 2011 Mar 24;80(2):83-90. Epub 2010 Sep 24.

Flow Cytometry Unit, Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA.

View Article
March 2011

Variables in the quantification of CD4 in normals and hairy cell leukemia patients.

Cytometry B Clin Cytom 2011 Jan;80(1):51-6

Chemical Science and Technology Laboratory, National Institute of Standards and Technology, Gaithersburg, Maryland 20899-8312, USA.

View Article
January 2011

Role of flow cytometry of peripheral blood and bone marrow aspirates in early myeloma.

Semin Hematol 2011 Jan;48(1):32-8

Flow Cytometry Unit, Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.

View Article
January 2011

Cytotoxicity of the anti-CD22 immunotoxin HA22 (CAT-8015) against paediatric acute lymphoblastic leukaemia.

Br J Haematol 2010 Aug 7;150(3):352-8. Epub 2010 Jun 7.

Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892-4264, USA.

View Article
August 2010

Visual inspection versus quantitative flow cytometry to detect aberrant CD2 expression in malignant T cells.

Cytometry B Clin Cytom 2010 May;78(3):169-75

Flow Cytometry Unit, Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA.

View Article
May 2010

25-Gauge transconjunctival sutureless vitrectomy for the diagnosis of intraocular lymphoma.

Br J Ophthalmol 2010 May;94(5):633-8

Laboratory of Immunology, National Eye Institute, National Institutes of Health, Building 10, 10N-112, 10 Center Drive, Bethesda, MD 20892, USA.

View Article
May 2010

Minimal residual disease detection by flow cytometry in adult T-cell leukemia/lymphoma.

Am J Clin Pathol 2010 Apr;133(4):592-601

Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.

View Article
April 2010

Anti-CD22 immunotoxin RFB4(dsFv)-PE38 (BL22) for CD22-positive hematologic malignancies of childhood: preclinical studies and phase I clinical trial.

Clin Cancer Res 2010 Mar 9;16(6):1894-903. Epub 2010 Mar 9.

Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892-1104, USA.

View Article
March 2010

VH4-34+ hairy cell leukemia, a new variant with poor prognosis despite standard therapy.

Blood 2009 Nov 10;114(21):4687-95. Epub 2009 Sep 10.

Laboratories of Molecular Biology, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.

View Article
November 2009

Persistent non-neoplastic gammadelta-T cells in cerebrospinal fluid of a patient with hepatosplenic (gammadelta) T cell lymphoma: a case report with 6 years of flow cytometry follow-up.

Int J Clin Exp Pathol 2009 Oct 15;3(1):110-6. Epub 2009 Oct 15.

Laboratory of Pathology, Hematopathology Section, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD 20892, USA.

View Article
October 2009

Phase II trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with hairy cell leukemia.

J Clin Oncol 2009 Jun 4;27(18):2983-90. Epub 2009 May 4.

Laboratory of Molecular Biology, Laboratory of Clinical Pathology, and Medicine Branch, National Cancer Institute, NIH, Bethesda, MD 20892, USA.

View Article
June 2009

Variable CD52 expression in mature T cell and NK cell malignancies: implications for alemtuzumab therapy.

Br J Haematol 2009 Apr 19;145(2):173-9. Epub 2009 Feb 19.

Flow Cytometry Unit, Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.

View Article
April 2009

EBV-related lymphoproliferative disease complicating therapy with the anti-CD2 monoclonal antibody, siplizumab, in patients with T-cell malignancies.

Clin Cancer Res 2009 Apr 17;15(7):2514-22. Epub 2009 Mar 17.

Metabolism Branch, Center for Cancer Research, Laboratory of Pathology, National Cancer Institute, Bethesda, Maryland and MedImmune, Inc, Gaithersburg, Maryland, USA.

View Article
April 2009

Novel CD19 expression in a peripheral T cell lymphoma: A flow cytometry case report with morphologic correlation.

Cytometry B Clin Cytom 2009 Mar;76(2):142-9

Flow Cytometry Unit, Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.

View Article
March 2009

PRAME expression in hairy cell leukemia.

Leuk Res 2008 Sep 4;32(9):1400-6. Epub 2008 Mar 4.

Laboratories of Molecular Biology and Clinical Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892-4255, United States.

View Article
September 2008

TIMP1 induces CD44 expression and the activation and nuclear translocation of SHP1 during the late centrocyte/post-germinal center B cell differentiation.

Cancer Lett 2008 Sep 23;269(1):37-45. Epub 2008 May 23.

Department of Pathology, Korea University Ansan Hospital, 516 Gojan-1 Dong, Danwon-Gu, Gyeonggi-Do, Ansan 425-707, Republic of Korea.

View Article
September 2008

Soluble CD22 as a tumor marker for hairy cell leukemia.

Blood 2008 Sep 2;112(6):2272-7. Epub 2008 Jul 2.

Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20854-4255, USA.

View Article
September 2008

Flow cytometric immunophenotyping of cerebrospinal fluid.

Curr Protoc Cytom 2008 Jul;Chapter 6:Unit 6.25

Department of Medical Oncology, Erasmus Medical Center, Rotterdam, The Netherlands.

View Article
July 2008

B-cell repertoire and clonal analysis in unaffected first degree relatives in familial chronic lymphocytic leukaemia kindred.

Br J Haematol 2007 Dec 17;139(5):820-3. Epub 2007 Oct 17.

Center for Biologics Evaluation and Research, US Food and Drug Administration, NIH, Bethesda, MD, USA.

View Article
December 2007

Bioethical considerations of monoclonal B-cell lymphocytosis: donor transfer after haematopoietic stem cell transplantation.

Br J Haematol 2007 Dec;139(5):824-31

Experimental Transplantation and Immunology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.

View Article
December 2007